Martin Štěrba

8PUBLICATIONS
28CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 23, 2026
Pharmacological correlates of topoisomerase II-directed protection against anthracycline-induced DNA damage and cardiotoxicity: a comparative evaluation of catalytic topoisomerase II inhibitors.

|Jul 24, 2026
sGC stimulator BAY 41-8543 improves survival and ventricular function in a rat model of doxorubicin-induced cardiomyopathy with nephrotic syndrome.

|Dec 08, 2021
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.

Zuzana Pokorná, Petra Kollárová-Brázdová, Olga Lenčová-Popelová

|Sep 23, 2021
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.

Eduard Jirkovský, Anna Jirkovská, Hana Bavlovič-Piskáčková

|Jul 28, 2021
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.

Petra Kollárová-Brázdová, Olga Lenčová-Popelová, Galina Karabanovich

|Apr 08, 2020
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.

Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich

Pageof 2

Frequent Collaborators

3 joint publications

Veronika Skalická

3 joint publications

Jan Kubeš

3 joint publications

Jaroslav Roh

3 joint publications

Petra Štěrbová-Kovaříková